CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase
The research leading to these results has mainly received funding from the European Union Seventh Framework Programme [FP7/2007–2013] under Grant Agreement no 306242-NGS-PTL. In addition, this work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias PI15/01471, PI18/01500, I...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2019 |
| Country: | España |
| Institution: | Universitat Pompeu Fabra |
| Repository: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/41729 |
| Online Access: | http://hdl.handle.net/10230/41729 http://dx.doi.org/10.1038/s41375-018-0255-1 |
| Access Level: | Open access |
| Keyword: | Leucèmia |
| _version_ | 1878731383954735104 |
|---|---|
| author | Hernández-Sánchez, María |
| author2 | Kotaskova, Jana Rodríguez, Ana E. Radova, Lenka Tamborero Noguera, David Abáigar, María Plevova, Karla Benito, Rocío Tom, Nikola Quijada-Álamo, Miguel Bikos, Vasileos Martín, Ana África Pal, Karol García de Coca, Alfonso Doubek, Michael López Bigas, Núria Hernández-Rivas, Jesús María Pospisilova, Sarka |
| author2_role | author author author author author author author author author author author author author author author author author |
| author_browse | Abáigar, María Benito, Rocío Bikos, Vasileos Doubek, Michael García de Coca, Alfonso Hernández-Rivas, Jesús María Hernández-Sánchez, María Kotaskova, Jana López Bigas, Núria Martín, Ana África Pal, Karol Plevova, Karla Pospisilova, Sarka Quijada-Álamo, Miguel Radova, Lenka Rodríguez, Ana E. Tamborero Noguera, David Tom, Nikola |
| author_facet | Hernández-Sánchez, María Kotaskova, Jana Rodríguez, Ana E. Radova, Lenka Tamborero Noguera, David Abáigar, María Plevova, Karla Benito, Rocío Tom, Nikola Quijada-Álamo, Miguel Bikos, Vasileos Martín, Ana África Pal, Karol García de Coca, Alfonso Doubek, Michael López Bigas, Núria Hernández-Rivas, Jesús María Pospisilova, Sarka |
| author_role | author |
| collection | Repositorio Digital de la UPF |
| description | The research leading to these results has mainly received funding from the European Union Seventh Framework Programme [FP7/2007–2013] under Grant Agreement no 306242-NGS-PTL. In addition, this work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias PI15/01471, PI18/01500, Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF) “Una manera de hacer Europa”, “Consejería de Educación, Junta de Castilla y León” (SA085U16), “Proyectos de Investigación del SACYL”, Spain: GRS 994/A/14, BIO/SA10/14, BIO/SA31/13, GRS 1172/A/15,“Fundación Memoria Don Samuel Solórzano Barruso”, by grants (RD12/0036/0069) from Red Temática de Investigación Cooperativa en Cáncer (RTICC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00233 and USAL "Programa XIII". M. Hernández-Sánchez is supported by FEHH-Janssen (“Sociedad Española de Hematología y Hemoterapia”). M Quijada-Álamo is supported by an “Ayuda Predoctoral de la Junta de Castilla y León” (JCYL-EDU/529/2017). We are grateful to I. Rodríguez, S. González, T.Prieto, M. Á. Ramos, A. Martín, A. Díaz, A. Simón, M.del Pozo, V. Gutiérrez and S. Pujante from Centro de Investigación del Cáncer, Salamanca, for their technical assistance. D. Tamborero is supported by project SAF2015–74072-JUN, which is funded by the Agencia Estatal de Investigación (AEI) and Fondo Europeo de Dearrollo Regional (FEDER). This work was supported by Seventh Framework Programme (NGS-PTL/2012–2015/no.306242) and Ministry of Education, Youth and Sports (2013–2015, no. 7E13008); by the Ministry of Education, Youth and Sports of the Czech Republic under the CEITEC 2020 project (LQ1601); by the Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705); by the Specific University Research (nr. MUNI/A/0968/2017) provided by MEYS; and by the project CZ.02.1.01/0.0/0.0/16_013/0001634 National Center for Medical Genomic - modernization of infrastructure and research of genetic variation in the population, funded by OP RDE. We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining the scientific data presented in this paper. We acknowledge S. Takacova from CEITEC MU for her help with the sample selection and processing. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_2e7b352ed6cdc3537e0aa9fdff2a7891 |
| institution | Universitat Pompeu Fabra |
| instname_str | Universitat Pompeu Fabra |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:repositori.upf.edu:10230/41729 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Nature Research |
| publisherStr | Nature Research |
| reponame_str | Repositorio Digital de la UPF |
| spelling | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase Hernández-Sánchez, María Kotaskova, Jana Rodríguez, Ana E. Radova, Lenka Tamborero Noguera, David Abáigar, María Plevova, Karla Benito, Rocío Tom, Nikola Quijada-Álamo, Miguel Bikos, Vasileos Martín, Ana África Pal, Karol García de Coca, Alfonso Doubek, Michael López Bigas, Núria Hernández-Rivas, Jesús María Pospisilova, Sarka Leucèmia The research leading to these results has mainly received funding from the European Union Seventh Framework Programme [FP7/2007–2013] under Grant Agreement no 306242-NGS-PTL. In addition, this work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias PI15/01471, PI18/01500, Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF) “Una manera de hacer Europa”, “Consejería de Educación, Junta de Castilla y León” (SA085U16), “Proyectos de Investigación del SACYL”, Spain: GRS 994/A/14, BIO/SA10/14, BIO/SA31/13, GRS 1172/A/15,“Fundación Memoria Don Samuel Solórzano Barruso”, by grants (RD12/0036/0069) from Red Temática de Investigación Cooperativa en Cáncer (RTICC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00233 and USAL "Programa XIII". M. Hernández-Sánchez is supported by FEHH-Janssen (“Sociedad Española de Hematología y Hemoterapia”). M Quijada-Álamo is supported by an “Ayuda Predoctoral de la Junta de Castilla y León” (JCYL-EDU/529/2017). We are grateful to I. Rodríguez, S. González, T.Prieto, M. Á. Ramos, A. Martín, A. Díaz, A. Simón, M.del Pozo, V. Gutiérrez and S. Pujante from Centro de Investigación del Cáncer, Salamanca, for their technical assistance. D. Tamborero is supported by project SAF2015–74072-JUN, which is funded by the Agencia Estatal de Investigación (AEI) and Fondo Europeo de Dearrollo Regional (FEDER). This work was supported by Seventh Framework Programme (NGS-PTL/2012–2015/no.306242) and Ministry of Education, Youth and Sports (2013–2015, no. 7E13008); by the Ministry of Education, Youth and Sports of the Czech Republic under the CEITEC 2020 project (LQ1601); by the Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705); by the Specific University Research (nr. MUNI/A/0968/2017) provided by MEYS; and by the project CZ.02.1.01/0.0/0.0/16_013/0001634 National Center for Medical Genomic - modernization of infrastructure and research of genetic variation in the population, funded by OP RDE. We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining the scientific data presented in this paper. We acknowledge S. Takacova from CEITEC MU for her help with the sample selection and processing. Nature Research http://hdl.handle.net/10230/41729 http://dx.doi.org/10.1038/s41375-018-0255-1 |
| spellingShingle | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase Hernández-Sánchez, María Leucèmia |
| status_str | publishedVersion |
| title | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase |
| title_full | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase |
| title_fullStr | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase |
| title_full_unstemmed | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase |
| title_short | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase |
| title_sort | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase |
| topic | Leucèmia |
| topic_facet | Leucèmia |
| url | http://hdl.handle.net/10230/41729 http://dx.doi.org/10.1038/s41375-018-0255-1 |